Preoperative PSMA PET/CT As Triage for EPLND in Patients Scheduled for RALP (PrePSMA)

Extended pelvic lymph node dissection (ePLND) is considered the gold standard for nodal staging in men with prostate cancer (PCa). The aim of this project is to determine if preoperative prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomograpy (CT) can safely replace ePLND as a staging method in PCa patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP).

Trial Details

NCT ID
NCT06398613
Phase
NA
Sponsor
Oslo University Hospital
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • extended pelvic lymph node dissection (ePLND)
Locations (sample)
  • Oslo, Norway|59.91273,10.74609

Key Eligibility Criteria

  • Biopsy proven diagnosed adenocarcinoma of the prostate
  • Indication for ePLND combined with RALP:
  • High-risk group (EAU) and including MRI findings indicating extra prostatic extension (Likert scale ≥4)
  • -ISUP GG 3 with ≥1 of the following unfavourable risk factors

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →